Rebif delays conversion to MS in patients

A board to discuss the Multiple Sclerosis modifying drug Rebif

Rebif delays conversion to MS in patients

Postby MSUK » Wed Oct 27, 2010 1:26 am

Rebif delays conversion to MS in patients with first clinical signs of the disease


Merck Serono, a division of Merck KGaA,Darmstadt, Germany, announced that the two-year Phase III REFLEX 1 study met its primary endpoint by demonstrating that Rebif® (interferon beta-1a) significantly delayed conversion to multiple sclerosis (MS) diagnosed according to the McDonald criteria 2 in patients with a first clinical event suggestive of the disease.

The international REFLEX study with 517 patients was conducted with the serum-free formulation of Rebif® 3, which was first introduced in 2007 and is now available in all European uni0n countries, Australia, Canada and Switzerland, as well as a number of countries in Asia, Latin America, Africa and the Middle East. The serum-free formulation of Rebif® is currently not available in the United States....Read More - ... ageid/1765
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm


Return to Rebif


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service